Track topics on Twitter Track topics that are important to you
SEP-363856 was discovered by Sunovion in collaboration with PsychoGenics using the in vivo phenotypic SmartCube platform and the artificial intelligence algorithms associated with it. Its breakthrough therapy designation
The post Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia appeared first on Pharmaceutical Business review.
Original Article: Sunovion’s SEP-363856 gets FDA breakthrough status for schizophreniaNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...